Xiaofan Gu

East China Normal University

H指数:13

被引数:641

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The endothelial activation and stress index as a risk factor for all-cause mortality in patients with anemia: a nationwide retrospective cross-sectional study

内皮激活和应激指数作为贫血患者全因死亡的风险因素：一项全国性回顾性横断面研究

Hematology

IF1.6

2025-12-310

PRE

Diagnostic performance and risk assessment of combined copeptin and high-sensitivity cardiac troponin I in Chinese emergency department

联合copeptin和高敏心肌肌钙蛋白I在急诊科的诊断性能与风险评估

IJC Heart & Vasculature

IF2.5

2025-09-080

PREAI

Ruxolitinib alleviated muscle atrophy in cancer cachexia by inhibiting IL-6/JAK/STAT3 signaling pathway in mice

鲁索利替尼通过抑制小鼠中IL-6/JAK/STAT3信号通路，缓解了癌症恶病质中的肌肉萎缩。

JOURNAL OF PHARMACY AND PHARMACOLOGY

IF3.2

2025-08-010

PRE

Endothelial Activation Stress Index predicts all-cause and cardiovascular mortality in patients with diabetes: A nationwide study

内皮激活应激指数预测糖尿病患者全因和心血管死亡率：一项全国性研究

Journal of Diabetes Investigation

IF3

2025-07-300

Endothelial Activation and Stress Index Predicts All-Cause and Cardiovascular Mortality in Hypertensive Individuals: A Nationwide Study

内皮激活与应激指数可预测高血压人群的全因和心血管死亡率：一项全国性研究

JOURNAL OF CLINICAL HYPERTENSION

IF2.5

2025-04-240

OAAI

Novel oral compound Z526 mitigates cancer-associated cachexia via intervening NF-KB signaling and oxidative stress

GENES & DISEASES

IF9.4

2025-03-010

OAAI

An Evaluation of Eco-Environmental Quality Based on the Fused Remote Sensing Ecological Index (FRSEI) in the Jinjie Coal Mine Area, Northwest China

WATER

IF3

2025-01-150

Neutrophil-lymphocyte ratio is a predictor for all-cause and cardiovascular mortality in individuals with prediabetes in a National study

一项全国性研究中，中性粒细胞-淋巴细胞比率是糖尿病前期患者全因死亡率和心血管死亡率的预测指标

ENDOCRINE

IF2.9

2024-10-230

PRE

Compound Z526 alleviates chemotherapy-induced cachectic muscle loss by ameliorating oxidative stress-driven protein metabolic imbalance and apoptosis

EUROPEAN JOURNAL OF PHARMACOLOGY

IF4.7

2024-07-012

PRE

Paeoniflorin alleviated muscle atrophy in cancer cachexia through inhibiting TLR4/NF-κB signaling and activating AKT/mTOR signaling

芍药苷通过抑制TLR4/nf-κb信号通路和激活AKT/mTOR信号通路减轻癌性恶病质肌肉萎缩

TOXICOLOGY AND APPLIED PHARMACOLOGY

IF3.4

2024-03-012

PRE

Carnosol analogue WK-63 alleviated cancer cachexia by inhibiting NF-κB and activating AKT pathways in muscle while inhibiting NF-κB and AMPK pathways in adipocyte

TOXICOLOGY AND APPLIED PHARMACOLOGY

IF3.4

2023-11-010

PRE

Corylifol A ameliorates muscle atrophy by inhibiting TAOK1/p38-MAPK/FoxO3 pathway in cancer cachexia

Corylifol A通过抑制TAOK1/p38-MAPK/FoxO3途径改善癌症恶病质中的肌肉萎缩

JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE

IF9.1

2023-07-137

Atractylenolide I ameliorates cancer cachexia through inhibiting biogenesis of IL-6 and tumour-derived extracellular vesicles

JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE

IF9.1

2022-09-0926

GDF-15 in tumor-derived exosomes promotes muscle atrophy via Bcl-2/caspase-3 pathway

CELL DEATH DISCOVERY

IF7

2022-04-0438

OAAI

The critical role of STAT3 in biogenesis of tumor-derived exosomes with potency of inducing cancer cachexia in vitro and in vivo

ONCOGENE

IF7.3

2022-01-1629

PRE

Bile acid metabolism dysregulation associates with cancer cachexia: roles of liver and gut microbiome

胆汁酸代谢失调与癌症恶病质相关: 肝脏和肠道微生物组的作用

JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE

IF9.1

2021-09-2840

OAAI

Cancer-derived exosome miRNAs induce skeletal muscle wasting by Bcl-2-mediated apoptosis in colon cancer cachexia

MOLECULAR THERAPY-NUCLEIC ACIDS

IF0

2021-06-0159

OAAI

Autophagy inhibition and microRNA-199a-5p upregulation in paclitaxel-resistant A549/T lung cancer cells

紫杉醇耐药肺癌A549/T细胞自噬抑制及microRNA-199a-5p上调

ONCOLOGY REPORTS

IF3.9

2021-06-0116

OAAI

Carnosol and its analogues attenuate muscle atrophy and fat lipolysis induced by cancer cachexia

鼠尾草酚及其类似物减轻癌性恶病质引起的肌肉萎缩和脂肪分解

JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE

IF9.1

2021-05-0534

OAAI

Design, synthesis, and structure activity relationship (SAR) studies of novel imidazo [1,2-a] pyridine derivatives as Nek2 inhibitors

BIOORGANIC & MEDICINAL CHEMISTRY

IF3

2020-12-019

PREAI

Xiaofan Gu

个人简介

教育背景

工作经历

荣誉奖项

研究方向